Skip to main navigation
iTeos Therapeutics - Cancer Immunotherapies by Design iTeos Therapeutics - Cancer Immunotherapies by Design

Main Nav

  • Home
  • About us
    • Overview
    • Management team
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Pipeline
    • Pipeline
    • Clinical trials
    • A2A Receptor Antagonist
    • TIGIT antagonist monoclonal antibody
    • Preclinical pipeline
  • Technology
    • Cancer Immunotherapy & Immunosuppression
    • Scientific Publications
  • Investors
    • News & Events
    • Stock Information
    • Financials
    • Governance
    • Investor Resources
  • Join the iTeos Team
  • Contact us

Main Nav

  • Home
  • About us
    • Overview
    • Management team
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Pipeline
    • Pipeline
    • Clinical trials
    • A2A Receptor Antagonist
    • TIGIT antagonist monoclonal antibody
    • Preclinical pipeline
  • Technology
    • Cancer Immunotherapy & Immunosuppression
    • Scientific Publications
  • Investors
    • News & Events
    • Stock Information
    • Financials
    • Governance
    • Investor Resources
  • Join the iTeos Team
  • Contact us
Skip to main content

sub Financials

  • SEC Filings
  • Quarterly Results
  • Annual Reports

Quarterly Results

Quarterly Results

Show all

2020

Q3 Earnings

  • iTeos Reports Third Quarter 2020 Financial Results and Provides Business Update

Q2 Earnings

  • iTeos Reports Second Quarter 2020 Financial Results and Provides Business Update
© 2021 iTeos Therapeutics. iTeos, iTeos logo and Cancer Immunotherapies By Design are trademarks of iTeos Therapeutics Inc.

Socials

LinkedIn Twitter

Footer Nav

Privacy policy Terms of use